Transcription inhibitors and inflammatory cell activity
File(s)
Author(s)
Type
Journal Article
Abstract
Inflammation is a central feature of asthma and chronic obstructive pulmonary disease (COPD). Despite recent advances in the knowledge of the pathogenesis of asthma and COPD, much more research on the molecular mechanisms of asthma and COPD are needed to aid the logical development of new therapies for these common and important diseases, particularly in COPD where no new effective treatments currently exist. In the future the role of the activation/repression of different transcription factors and the genetic regulation of their expression in asthma and COPD may be an increasingly important aspect of research, as this may be one of the critical mechanisms regulating the expression of different clinical phenotypes and their responsiveness to therapy, particularly to anti-inflammatory drugs.
Date Issued
2019-06-14
Date Acceptance
2019-05-15
Citation
Current Opinion in Pharmacology, 2019, 46, pp.82-89
ISSN
1471-4892
Publisher
Elsevier
Start Page
82
End Page
89
Journal / Book Title
Current Opinion in Pharmacology
Volume
46
Copyright Statement
© 2019 Elsevier Ltd. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence http://creativecommons.org/licenses/by-nc-nd/4.0/.
Sponsor
Wellcome Trust
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/31207387
PII: S1471-4892(18)30143-7
Grant Number
093080/Z/10/Z
Subjects
1115 Pharmacology and Pharmaceutical Sciences
Pharmacology & Pharmacy
Publication Status
Published online
Coverage Spatial
England
Date Publish Online
2019-06-14